Clinical

Patients who were treatment naive or had switched to rituximab saw short-term results of reduced disease activity in multiple sclerosis.

A recent study identified persistent myocardial fibroblast activation in patients with heart failure with reduced ejection fraction, with distinct patterns by etiology.

Experts at AMCP 2026 outlined volatility across the health care landscape that may impact the upcoming midterm elections.

Community response teams can adapt hospital rapid response principles for managed care organizations, targeting rising-risk members to prevent costly clinical deterioration and generate measurable cost savings.

Two posters presented at AMCP 2026 found low dry eye disease (DED) treatment uptake and frequent discontinuation among Medicare patients, whereas comorbid DED did not affect glaucoma adherence.

A clinical pharmacy leader outlines 8 interdependent domains institutions must master to build financially sustainable, patient-accessible CGT programs.

Two posters presented at AMCP 2026 suggest improving GLP-1 adherence and access may enhance outcomes and lower obesity-related costs.

Bone-only, osteoblastic disease and the absence of prior ARPI exposure define the optimal radium-223 candidate, while sequencing relative to lutetium-177 PSMA-617 remains an active area of investigation.

Benjamin Lockshin, MD, FAAD, examines the non-clinical reasons driving real-world treatment discontinuation and explains how clinicians use primary versus secondary loss of efficacy to guide biologic sequencing decisions across IL-23 and IL-17 classes.

Benjamin Lockshin, MD, FAAD, reviews real-world persistence data for tildrakizumab, discussing the interplay of clinical efficacy, insurance coverage, and buy-and-bill reimbursement in driving long-term treatment durability—particularly among Medicare and Medicaid patients.

DOR/ISL exemplifies how 2-drug regimens could meet the complex needs of an aging HIV population.

The mCRPC section's reorganization by prior treatment exposure reflects how ARPI and docetaxel use in the hormone-sensitive setting now defines—and constrains—options in the castration-resistant phase.

Psychological effects of alopecia areata should be looked into in the future for patients who live with the condition.

Housing and transportation barriers were linked to lower CRC screening rates, especially among adults aged 50 to 64.

Finerenone lowered cardiovascular death and HF events irrespective of coronary heart disease status but did not reduce atherothrombotic outcomes.

Two AAD 2026 posters highlight persistent melanoma disparities: men have worse survival, whereas minority patients are less likely to receive home or hospice end-of-life care.

At-home phototherapy is more convenient than in-office care, and investigators found its one-time costs are also far less than the cost of care in a clinic.

Steven Daveluy, MD, discusses 3-year findings that show 86% of patients remained HS flare-free throughout treatment, reinforcing the case for early intervention.

A real-world study has found that personalizing ibrutinib doses based on patient health does not compromise survival outcomes in chronic lymphocytic leukemia (CLL).

Both Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scores improved after treatment.

Phase 3 CANOPY data show pemivibart safely prevented COVID-19 in patients with CLL, supporting EUA use for immunocompromised populations.

Poor outcomes could be predicted based on the presence of ectopic germinal centers in the thymus in patients with thymoma-associated myasthenia gravis.

Sequential therapy of ranibizumab and a dexamethasone implant improved results in macular edema secondary to non–ischemic retinal vein occlusion.

JoAnn Manson, MD, shares findings from the VIVID trial on vitamin D, the timing of use, and its potential to reduce long COVID risk and symptom severity.

Ajai Chari, MD, discusses the teclistamab-daratumumab approval, highlighting durable remissions, infection management, and the need for community oncologist uptake.